Analysts Adjust Price Targets for Oculis Stock Following Oculis's financial results, H.C. Wainwright reduced its price target to $29, while Stifel maintained its $35 target. The company continues advancing its pipeline, including the potential FDA submission of OCS-01 in early 2025. Analysts remain bullish, citing promising clinical developments and a robust liquidity position.456